Saneca Pharmaceuticals has been acquired by AZC Group
Eterus Capital, a.s. has sold Saneca Pharmaceuticals, a.s. to AZC Group.
Saneca is a pharmaceutical contract manufacturing company active in the development, production, registration and distribution of generic medicines and active pharmaceutical ingredients. Saneca also owns a portfolio of cosmetics and generic products.
Based in Slovakia, AZC is an industrial business group operating in over 20 countries.
Founded in 2008, Eterus Capital is an investor targeting small and medium-sized companies with growth potential, that have successfully proved their business concept. The fund only invests in minority positions, while management control always remains in the hands of the original shareholders.
Oaklins’ team in Slovakia acted as the exclusive sell-side advisor in this transaction.
Talk to the deal team
Related deals
Bayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn moreMark Climate Technology has acquired Heber GmbH
Heber GmbH has been acquired by Mark Climate Technology, a specialist in climate control systems and a portfolio company of Bolster Investment Partners. This partnership strengthens the positions of both companies in the global market for innovative and sustainable climate solutions, as well as creating unique synergies. Mark Climate's expertise in standardized, scalable solutions is enhanced by Heber's emphasis on customer-specific customization.
Learn moreGrupo Veta 2017 S.L. has been acquired by MSA Mizar
The Franco-Belgian fund Kartesia has sold Grupo Veta 2017 S.L. to the Italian group MSA Mizar. Kartesia, the main shareholder of Veta+ together with its founding partner, has sold 100% of the capital. For MSA Mizar, this transaction represents the consolidation of its presence in Spain, the entry into the multi-risk claims management market and the opportunity to apply Veta+’s expertise to other European markets.
Learn more